Phenylketonuria (PKU) is a metabolic disease of genetic origin. This is a rare disease (incidence 1 / 16000 births) which is the subject of a systematic neonatal screening in France, because it is treatable by a diet low in phenylalanine. This plan is required upon confirmation of diagnosis and continued until the age of 8 years. The current trend is to continue the scheme at least until adolescence. Unlike other countries, in France there are no recommendations for a plan "for life". Knowledge about the natural history of PKU in adulthood, the effects of pediatric age, the frequency of complicated shapes, and prognostic factors are poorly documented. On the other hand, there is no consensus on the therapeutic management of this disease in adulthood and monitoring that could be directed towards the detection of neurological disorders and nutrition. Social integration and quality of life of adults PKU patients living in France have not been studied.
The aim off this study is to follow a French cohort of young adult patients with PKU to: * Describe the evolution of the disease in adulthood and neurological complications associated neuropsychological detect, investigate the prognostic factors for complications * Describe the metabolic balance of patients * Collect data on nutritional status, * Detect osteoporosis * Studying social integration and quality of life of adult patients with PKU * Collect biological samples for further study (markers of bone turnover) Design: Cohort : Duration of the inclusion period: 2 years Duration of subject participation: 5 years Total duration of the study: 7 years JUDGING CRITERIA: * Complications associated with PKU in adult * Evolution of neuropsychometric scores * Bone mineral density by densitometry * Measuring the quality of life of patients
Study Type
OBSERVATIONAL
Enrollment
220
CHRU-Hôpital Bretonneau - Service de Médecine Interne-Nutrition
Tours, Centre-Val de Loire, France
CHU-ANGERS -Médecine Interne
Angers, France
CHU_Service de Médecine Interne Nutrition A2-Hôpital du Haut Levèque
Bordeaux, France
CHU du Morvan-Département de Pédiatrie et génétique médicale,
Brest, France
Hôpital Femme-Mère-Enfant-Centre de Référence des Maladies Héréditaires du Métabolisme de Lyon
Bron, France
CHU de Dijon--Hôpital des Enfants-Centre de Génétique
Dijon, France
CHU de Grenoble-Hôpital MICHALLON-Unité de Neurologie Générale
Grenoble, France
CHU de LILLE-Hôpital Claude HURIEZ-Service d'Endocrinologie
Lille, France
APHM-Hôpital de la Conception -Médecine Interne
Marseille, France
CHU-Service de Réanimation Pédiatrique / Néonatalogie, Consultation spécialisée en Maladies Héréditaires du Métabolisme
Nantes, France
...and 6 more locations
Evaluate a possible cognitive decline and incidence of neurological complications
Time frame: 5 years
Determine the prognostic factors of neurological complications
Determine the prognostic factors of these complications, and the impact of the disease and its management on the quality of life (SF-36) and social and professional integration of patients.
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.